Hypertensive heart disease and obesity: A complex interaction between hemodynamic and not hemodynamic factors

High Blood Pressure and Cardiovascular Prevention

Volumn 21, Issue 2, 2014, Pages 81-87

  Sarzani, Riccardo ^a   Bordicchia, Marica ^a   Spannella, Francesco ^a   Dessì Fulgheri, Paolo ^a   Fedecostante, Massimiliano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Adipocyte; Cardiovascular risk; Hypertensive heart disease; Natriuretic peptides; Obesity

Indexed keywords

ADIPOCYTE; CARDIOVASCULAR RISK; ELEVATED BLOOD PRESSURE; HEART DISEASE; HEART HEMODYNAMICS; HEART INJURY; HUMAN; HYPERTENSION; HYPERTENSIVE HEART DISEASE; HYPOTHESIS; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; BLOOD PRESSURE; COMORBIDITY; HEART DISEASES; HEMODYNAMICS; METABOLISM; PATHOPHYSIOLOGY; PREVALENCE; RISK FACTOR; SIGNAL TRANSDUCTION;

NATRIURETIC FACTOR;

ADIPOSITY; ANIMALS; BLOOD PRESSURE; COMORBIDITY; HEART DISEASES; HEMODYNAMICS; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; NATRIURETIC PEPTIDES; OBESITY; PREVALENCE; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84904614308     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-014-0054-3     Document Type: Review

References (57)

1. World health statistics 2013. World Health Organization; 2013.
2. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28:w822-31.
3. Gallus S, Odone A, Lugo A, Bosetti C, Colombo P, Zuccaro P, La Vecchia C. Overweight and obesity prevalence and determinants in Italy: an update to 2010. Eur J Nutr. 2013;52(2):677-85.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-9. (Pubitemid 34251969)
5. The Italian Cardiovascular Epidemiological Observatory. It Heart J. 2004; (suppl 3):49S-52S.
6. Stamler J, Dyer AR, Shekelle RB, Neaton J, Stamler R. Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. Cardiology. 1993;82:191-222. (Pubitemid 23182028)
7. l'Allemand-Jander D. Clinical diagnosis of metabolic and cardiovascular risks in overweight children: early development of chronic diseases in the obese child. Int J Obes (Lond). 2010;34(suppl 2):S32-6.
8. Juonala M, Magnussen CG, Berenson GS, Venn A, Burns TL, Sabin MA, Srinivasan SR, Daniels SR, Davis PH, Chen W, Sun C, Cheung M, Viikari JS, Dwyer T, Raitakari OT. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011;365:1876-85.
9. Bramlage P, Pittrow D, Wittchen HU, Kirch W, Boehler S, Lehnert H, Hoefler M, Unger T, Sharma AM. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17:904-10. (Pubitemid 39366016)
10. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the night-time blood pressure. Hypertension. 2011;57:3-10.
11. Kotsis V, Stabouli S, Bouldin M, Low A, Toumanidis S, Zakopoulos N. Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension. 2005;45:602-7. (Pubitemid 40411267)
12. Mokhlesi B. Obesity hypoventilation syndrome: a state-of-the-art review. Resp Care. 2010;55:1347-62.
13. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;2013(31):1281-357.
14. Aucott L, Rothnie H, McIntyre L, Thapa M, Waweru C, Gray D. Long-term weight loss from lifestyle intervention benefits blood pressure? A systematic review. Hypertension. 2009;54:756-62.
15. Siebenhofer A, Jeitler K, Berghold A, Waltering A, Hemkens LG, Semlitsch T, Pachler C, Strametz R, Horvath K. Long-term effects of weight-reducing diets in hypertensive patients. Cochrane Database Syst Rev. 2011;7(9):CD008274.
16. Lewington S, Clarke R, Qiziibash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13. (Pubitemid 35472129)
17. Gleiberman L. Blood pressure and dietary salt in human populations. Ecol Food Nutr. 1973;2:143-56.
18. Dyer AR, Elliott P, Marmot M, Kesteloot H, Stamler R, Stamler J. Commentary: strength and importance of the relation of dietary salt to blood pressure. Intersalt Steering and Editorial Committee. BMJ. 1996;29(312):1661-4. (Pubitemid 26229462)
19. Donfrancesco C, Ippolito R, Lo Noce C, Palmieri L, Iacone R, Russo O, Vanuzzo D, Galletti F, Galeone D, Giampaoli S, Strazzullo P. Excess dietary sodium and inadequate potassium intake in Italy: results of the MINISAL study. Nutr Metab Cardiovasc Dis. 2013;23:850-6.
20. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321:580-5. (Pubitemid 19212870)
21. Oliver WJ, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a "nosalt" culture. Circulation. 1975;52:146-51.
22. Pratt JH. Central role for ENaC in development of hypertension. J Am Soc Nephrol. 2005;16:3154-9. (Pubitemid 46179321)
23. Sarzani R, Guerra F, Mancinelli L, Buglioni A, Franchi E, Dessì-Fulgheri P. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. Am J Hypertens. 2012;25:818-26.
24. Díez J, Frohlich ED. A translational approach to hypertensive heart disease. Hypertension. 2010;55:1-8.
25. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res. 1993;27:341-8. (Pubitemid 23116130)
26. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation. 1993;88:993-1003. (Pubitemid 23264015)
27. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, Kottkamp H, Dhein S. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004;90:400-5. (Pubitemid 38406914)
28. De Simone G, Devereux RB, Chinali M, Roman MJ, Lee ET, Resnick HE, Howard BV. Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study. Nutr Metab Cardiovasc Dis. 2009;19:98-104.
29. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation. 1999;100:292-8. (Pubitemid 29340137)
30. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95:1247-52. (Pubitemid 27097837)
31. Lim JY, Prk SJ, Hwang HY, Park EJ, Nam JH, Kim J, Park SI. TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. J Mol Cell Cardiol. 2005;39:627-36. (Pubitemid 41331051)
32. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension. 2004;43:739-45. (Pubitemid 38405580)
33. Sciarretta S, Ferrucci A, Ciavarella GM, De Paolis P, Venturelli V, Tocci G, De Biase L, Rubattu S, Volpe M. Markers of inflammation and fibrosis are related to cardiovascular damage in hypertensive patients with metabolic syndrome. Am J Hypertens. 2007;20:784-91. (Pubitemid 46951019)
34. Guerra F, Mancinelli L, Angelini L, Fortunati M, Rappelli A, Dessì-Fulgheri P, Sarzani R. The association of left ventricular hypertrophy with metabolic syndrome is dependent on body mass index in hypertensive overweight or obese patients. PLoS ONE. 2011;6(1):e16630.
35. Sarzani R, Salvi F, Dessì-Fulgheri P, Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J Hypertens. 2008;26:831-43. (Pubitemid 351540757)
36. Dluhy RG, Williams GH. Aldosterone - villain or bystander? N Engl J Med. 2004;351:8-10. (Pubitemid 38857241)
37. Brilla CG, Rupp H, Funck R, Maisch B. The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur Heart J. 1995;16 Suppl O:107-9. (Pubitemid 26082358)
38. Sarzani R, Brecher P, Chobanian AV. Growth factor expression in aorta of normotensive and hypertensive rats. J Clin Invest. 1989;83:1404-8. (Pubitemid 19113058)
39. Takasaki I, Chobanian AV, Sarzani R, Brecher P. Effect of hypertension on fibronectin expression in the rat aorta. J Biol Chem. 1990;265:21935-9. (Pubitemid 120014245)
40. Sarzani R, Arnaldi G, Chobanian AV. Hypertension-induced changes of platelet-derived growth factor receptor expression in rat aorta and heart. Hypertension. 1991;17:888-95.
41. Sarzani R, Arnaldi G, Takasaki I, Brecher P, Chobanian AV. Effects of hypertension and aging on platelet-derived growth factor and platelet-derived growth factor receptor expression in rat aorta and heart. Hypertension. 1991;18:III93-9.
42. Glenn DJ, Wang F, Nishimoto M, Cruz MC, Uchida Y, Holleran WM, Zhang Y, Yeghiazarians Y, Gardner DG. A murine model of isolated cardiac steatosis leads to cardiomyopathy. Hypertension. 2011;57:216-22.
43. Sarzani R. The clinical significance of metabolic syndrome in hypertension: metabolic syndrome increases cardiovascular risk: the contrary position. High Blood Press Cardiovasc Prev. 2008;15:59-62.
44. Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, Lewicki JA. Physiological role of silent receptors of atrial natriuretic factor. Science. 1987;238:675-8. (Pubitemid 17158299)
45. Sarzani R, Paci VM, Dessi-Fulgheri P, Espinosa E, Rappelli A. Comparative analysis of atrial natriuretic peptide receptor expression in rat tissues. J Hypertens Suppl. 1993;11(5):S214-5. (Pubitemid 24024775)
46. Sarzani R, Dessì-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest. 1996;19:581-5. (Pubitemid 26408098)
47. Sarzani R, Paci VM, Zingaretti CM, Pierleoni C, Cinti S, Cola G, Rappelli A, Dessì-Fulgheri P. Fasting inhibits natriuretic peptides clearance receptor expression in rat adipose tissue. J Hypertens. 1995;13:1241-6. (Pubitemid 26003260)
48. Nakatsuji H, Maeda N, Hibuse T, Hiuge A, Hirata A, Kuroda Y, Kishida K, Kihara S, Funahashi T, Shimomura I. Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells. Biochem Biophys Res Commun. 2010;392:100-5.
49. Dessi-Fulgheri P, Sarzani R, Tamburrini P, Moraca A, Espinosa E, Cola G, Giantomassi L, Rappelli A. Plasma atrial natriuretic peptide and natriuretic peptide receptor gene expression in adipose tissue of normotensive and hypertensive obese patients. J Hypertens. 1997;15:1695-9. (Pubitemid 28029666)
50. Dessì-Fulgheri P, Sarzani R, Serenelli M, Tamburrini P, Spagnolo D, Giantomassi L, Espinosa E, Rappelli A. Low caloric diet enhances renal, hemodynamic, and humoral effects of exogenous atrial natriuretic peptide in obese hypertensives. Hypertension. 1999;33:658-62. (Pubitemid 29091643)
51. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EL, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation. 2007;115:1345-53. (Pubitemid 46648370)
52. Savoia C, Volpe M, Alonzo A, Rossi C, Rubattu S. Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Clin Sci. 2010;118:231-40.
53. Rubattu S, Sciarretta S, Morriello A, Calvieri C, Battistoni A, Volpe M. NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med. 2010;88:889-97.
54. Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, Yamauchi M, Smithies O. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci. 1999;96:7403-8. (Pubitemid 29299674)
55. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, Katsuki H, Nakao K. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci. 2000;97:4239-44. (Pubitemid 30226117)
56. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, Smithies O, Rockman HA, Maeda N. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest. 2001;107(8):975-84. (Pubitemid 32328002)
57. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessì-Fulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122:1022-36.